

Prognostic indicators in hepatocellular carcinoma: a sys

Liver International

29, 502-510

DOI: [10.1111/j.1478-3231.2008.01957.x](https://doi.org/10.1111/j.1478-3231.2008.01957.x)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Challenge and Hope in Radiotherapy of Hepatocellular Carcinoma. <i>Yonsei Medical Journal</i> , 2009, 50, 601.	0.9	57
2	Adaptive immunity in hepatocellular carcinoma: prognostic and therapeutic implications. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 1499-1510.	1.1	26
3	Clinical Staging of Hepatocellular Carcinoma. <i>Digestive Diseases</i> , 2009, 27, 131-141.	0.8	20
4	Prognostic scores for hepatocellular carcinoma: none is the winner. <i>Liver International</i> , 2009, 29, 478-480.	1.9	39
5	Portal hypertension and development of hepatocellular carcinoma: Factors influencing significance in prognostic models. <i>Journal of Hepatology</i> , 2009, 50, 848-849.	1.8	3
6	Management and Treatment of Patients With Cirrhosis and Portal Hypertension: Recommendations From the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program. <i>American Journal of Gastroenterology</i> , 2009, 104, 1802-1829.	0.2	215
7	Eastern asian expert panel opinion: designing clinical trials of molecular targeted therapy for hepatocellular carcinoma. <i>BMC Cancer</i> , 2010, 10, 620.	1.1	4
8	A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. <i>Hepatology</i> , 2010, 51, 1274-1283.	3.6	374
9	Course and prognosis of myasthenia gravis: a systematic review. <i>European Journal of Neurology</i> , 2010, 17, 913-921.	1.7	45
10	Diabetes mellitus as an independent prognostic predictor and its association with renal dysfunction in patients with hepatocellular carcinoma. <i>Liver International</i> , 2010, 30, 198-207.	1.9	30
11	Association of exogenous insulin or sulphonylurea treatment with an increased incidence of hepatoma in patients with hepatitis C virus infection. <i>Liver International</i> , 2010, 30, 479-486.	1.9	75
12	Update on new approaches in the management of hepatocellular carcinoma. <i>Hepatic Medicine: Evidence and Research</i> , 2010, 2, 163.	0.9	6
13	Molecular Classification and Novel Targets in Hepatocellular Carcinoma: Recent Advancements. <i>Seminars in Liver Disease</i> , 2010, 30, 035-051.	1.8	267
14	Prognostic prediction across a gradient of total tumor volume in patients with hepatocellular carcinoma undergoing locoregional therapy. <i>BMC Gastroenterology</i> , 2010, 10, 146.	0.8	33
15	Survival Rates Are Comparable After Radiofrequency Ablation or Surgery in Patients With Small Hepatocellular Carcinomas. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 79-86.	2.4	151
16	Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma. <i>Current Oncology</i> , 2011, 18, 228-240.	0.9	55
17	Prognostic Index for Portal Vein Tumor Thrombosis in Patients with Hepatocellular Carcinoma Treated with Radiation Therapy. <i>Journal of Korean Medical Science</i> , 2011, 26, 1014.	1.1	58
19	Predicting survival in patients with hepatocellular carcinoma treated by transarterial chemoembolisation. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 196-204.	1.9	50

#	ARTICLE	IF	CITATIONS
20	Hepatocellular carcinoma treated with sorafenib. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 1347-1348.	1.9	2
21	Prognostic Impact of Preoperative the Branched-Chain Amino Acid to the Tyrosine Ratio in Hepatocellular Carcinoma Patients after Initial Hepatectomy. <i>Journal of Gastrointestinal Surgery</i> , 2011, 15, 1433-1439.	0.9	14
22	Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib. <i>Journal of Translational Medicine</i> , 2011, 9, 120.	1.8	22
23	Early finding of chest wall metastasis of hepatocellular carcinoma in a woman by fluorodeoxyglucose-positron emission tomography scan: a case report. <i>Journal of Medical Case Reports</i> , 2011, 5, 147.	0.4	1
24	The Effect of Age on the Long-term Prognosis of Patients With Hepatocellular Carcinoma After Resection Surgery. <i>Archives of Surgery</i> , 2012, 147, 137.	2.3	60
25	Circulating Tumor Cells Measurements in Hepatocellular Carcinoma. <i>International Journal of Hepatology</i> , 2012, 2012, 1-16.	0.4	38
26	Prognostic Significance of Computed Tomography Scan-derived Splenic Volume in Hepatocellular Carcinoma Treated With Radiofrequency Ablation. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 789-795.	1.1	19
27	A novel and validated prognostic index in hepatocellular carcinoma: The inflammation based index (IBI). <i>Journal of Hepatology</i> , 2012, 57, 1013-1020.	1.8	164
28	Alterations of TP53 are associated with a poor outcome for patients with hepatocellular carcinoma: Evidence from a systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2012, 48, 2328-2338.	1.3	108
29	Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis. <i>Hepatology</i> , 2012, 56, 1371-1379.	3.6	130
30	Utilisation of search filters in systematic reviews of prognosis questions. <i>Health Information and Libraries Journal</i> , 2012, 29, 309-322.	1.3	18
31	Prognosis predictability of hepatocellular carcinoma according to staging systems in hepatitis B virus-endemic area. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2012, 36, 357-364.	0.7	1
32	Defining the severity of liver dysfunction in patients with hepatocellular carcinoma by the model for end-stage liver disease-derived systems. <i>Digestive and Liver Disease</i> , 2012, 44, 868-874.	0.4	10
33	High viral load is associated with poor overall and recurrence-free survival of hepatitis B virus-related hepatocellular carcinoma after curative resection: A prospective cohort study. <i>European Journal of Surgical Oncology</i> , 2012, 38, 683-691.	0.5	76
34	Prognosis of Patients with Hepatocellular Carcinoma. Validation and Ranking of Established Staging-Systems in a Large Western HCC-Cohort. <i>PLoS ONE</i> , 2012, 7, e45066.	1.1	58
35	The value of the Barcelona Clinic Liver Cancer and alpha-fetoprotein in the prognosis of hepatocellular carcinoma. <i>Revista Espanola De Enfermedades Digestivas</i> , 2012, 104, 298-304.	0.1	40
36	Hepatocellular Carcinoma: Methods of Circulating Tumor Cells (CTC) Measurements. , 0, , .		1
37	Influences of tobacco and alcohol use on hepatocellular carcinoma survival. <i>International Journal of Cancer</i> , 2012, 131, 2612-2621.	2.3	52

#	ARTICLE	IF	CITATIONS
38	First interim analysis of the GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 Clinical Practice, 2012, 66, 675-683.	0.8	102
39	A prognostic model for patients with hepatocellular carcinoma within the Milan criteria undergoing non-transplant therapies, based on 1106 patients. Alimentary Pharmacology and Therapeutics, 2012, 36, 551-559.	1.9	11
40	Neutrophil-to-lymphocyte ratio associated with mortality in early hepatocellular carcinoma patients after radiofrequency ablation. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 553-561.	1.4	122
41	Risk Factors, Clinical Features, and Prognosis of the Hepatocellular Carcinoma with Peritoneal Metastasis. Digestive Diseases and Sciences, 2012, 57, 813-819.	1.1	31
42	High intratumoral metastasis-associated in colon cancer-1 expression predicts poor outcomes of cryoablation therapy for advanced hepatocellular carcinoma. Journal of Translational Medicine, 2013, 11, 41.	1.8	38
43	Overview of data-synthesis in systematic reviews of studies on outcome prediction models. BMC Medical Research Methodology, 2013, 13, 42.	1.4	19
44	Prognostic value of C-reactive protein and neutrophil-to-lymphocyte ratio in patients with hepatocellular carcinoma. BMC Cancer, 2013, 13, 78.	1.1	95
45	Alcoholism worsens the survival of patients with hepatitis B virus and C virus-related hepatocellular carcinoma. Hepatology International, 2013, 7, 645-654.	1.9	17
46	¹⁸ F-Fluorodeoxyglucose PET/CT predicts tumour progression after transarterial chemoembolization in hepatocellular carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 865-873.	3.3	49
47	Total Tumor Volume Is a Better Marker of Tumor Burden in Hepatocellular Carcinoma Defined by the Milan Criteria. World Journal of Surgery, 2013, 37, 1348-1355.	0.8	26
48	Low Expression of PAI-2 as a Novel Marker of Portal Vein Tumor Thrombosis and Poor Prognosis in Hepatocellular Carcinoma. World Journal of Surgery, 2013, 37, 608-613.	0.8	9
49	Long-term effectiveness of resection and radiofrequency ablation for single hepatocellular carcinoma ≤ 3 cm. Results of a multicenter Italian survey. Journal of Hepatology, 2013, 59, 89-97.	1.8	241
50	680 CLINICAL CHARACTERISTICS, TREATMENT AND PROGNOSIS OF NON-B NON-C HEPATOCELLULAR CARCINOMA: A LARGE RETROSPECTIVE MULTICENTER COHORT STUDY. Journal of Hepatology, 2013, 58, S276.	1.8	2
51	N-WASP is highly expressed in hepatocellular carcinoma and associated with poor prognosis. Surgery, 2013, 153, 518-525.	1.0	23
52	LARP1 predict the prognosis for early-stage and AFP-normal hepatocellular carcinoma. Journal of Translational Medicine, 2013, 11, 272.	1.8	40
53	The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib. Digestive and Liver Disease, 2013, 45, 408-413.	0.4	31
54	Risk factors of poor prognosis and portal vein tumor thrombosis after curative resection of solitary hepatocellular carcinoma. Hepatobiliary and Pancreatic Diseases International, 2013, 12, 68-73.	0.6	13
55	Lobar Hepatocellular Carcinoma with Ipsilateral Portal Vein Tumor Thrombosis Treated with Yttrium-90 Glass Microsphere Radioembolization: Preliminary Results. International Journal of Hepatology, 2013, 2013, 1-8.	0.4	28

#	ARTICLE	IF	CITATIONS
56	Polymorphisms in the coding region of X-ray repair complementing group 4 and aflatoxin B1-related hepatocellular carcinoma. <i>Hepatology</i> , 2013, 58, 171-181.	3.6	39
57	Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis. <i>Annals of Oncology</i> , 2013, 24, 406-411.	0.6	126
58	Genetic Polymorphisms in DNA Repair Genes XRCC4 and XRCC5 and Aflatoxin B1-related Hepatocellular Carcinoma. <i>Epidemiology</i> , 2013, 24, 671-681.	1.2	58
59	MicroRNA-429 Modulates Hepatocellular Carcinoma Prognosis and Tumorigenesis. <i>Gastroenterology Research and Practice</i> , 2013, 2013, 1-10.	0.7	40
60	HCC-ART score, a simple, highly sensitive and specific test for early diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. <i>British Journal of Cancer</i> , 2013, 109, 1657-1665.	2.9	27
61	MACC1 as a Prognostic Biomarker for Early-Stage and AFP-Normal Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2013, 8, e64235.	1.1	30
62	Concurrent Activation of Acetylation and Tri-Methylation of H3K27 in a Subset of Hepatocellular Carcinoma with Aggressive Behavior. <i>PLoS ONE</i> , 2014, 9, e91330.	1.1	34
63	MicroRNAs in Nonalcoholic Fatty Liver Disease: Novel Biomarkers and Prognostic Tools during the Transition from Steatosis to Hepatocarcinoma. <i>BioMed Research International</i> , 2014, 2014, 1-14.	0.9	62
64	Vascular Invasion in Hepatocellular Carcinoma. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, 734-741.	1.1	68
65	Transarterial Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: Prognostic Factors in a Single-Center Study of 188 Patients. <i>BioMed Research International</i> , 2014, 2014, 1-8.	0.9	38
66	Tumor Size Does Not Independently Affect Long-Term Survival after Curative Resection of Solitary Hepatocellular Carcinoma Without Macroscopic Vascular Invasion. <i>World Journal of Surgery</i> , 2014, 38, 947-957.	0.8	44
67	Assessing Prognostic Significance of Preoperative Alpha-Fetoprotein in Hepatitis B-Associated Hepatocellular Carcinoma: Normal is not the New Normal. <i>Annals of Surgical Oncology</i> , 2014, 21, 986-994.	0.7	41
68	Clinical characteristics, outcome, and risk factors for early and late intrahepatic recurrence of female patients after curative resection of hepatocellular carcinoma. <i>Surgery</i> , 2014, 156, 651-660.	1.0	31
69	<sc>GIDEON</sc> (Global Investigation of therapeutic <sc>DE</sc> cisions in hepatocellular) Tj ETQq1 1 0.784314 rgBT /Overl Clinical Practice, 2014, 68, 609-617.	0.8	215
70	Hepatocellular carcinoma tumour markers: Current role and expectations. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2014, 28, 843-853.	1.0	89
71	Development of a novel score for early detection of hepatocellular carcinoma among high-risk hepatitis C virus patients. <i>Tumor Biology</i> , 2014, 35, 6501-6509.	0.8	9
72	Arterial Portography during Transarterial Chemoembolization: Still a Necessity in the Age of Contrast-enhanced Cross-sectional Imaging?. <i>Journal of Vascular and Interventional Radiology</i> , 2014, 25, 41-46.	0.2	3
73	A Comparison of Clinical Manifestations and Prognoses Between Patients with Hepatocellular Carcinoma and Child-Pugh Scores of 5 or 6. <i>Medicine (United States)</i> , 2014, 93, e348.	0.4	17

#	ARTICLE	IF	CITATIONS
74	Effects of Hepatitis B Virus Load on Hepatectomy. <i>Clinical Microbiology (Los Angeles, Calif)</i> , 2015, 04, .	0.2	0
75	Survival Analysis of Hepatocellular Carcinoma. <i>Chinese Medical Journal</i> , 2015, 128, 1793-1800.	0.9	25
76	Prognostic effect of preoperative sequential transcatheter arterial chemoembolization and portal vein embolization for right hepatectomy in patients with solitary hepatocellular carcinoma. <i>Korean Journal of Hepato-biliary-pancreatic Surgery</i> , 2015, 19, 59.	1.0	18
77	Sorafenib for the treatment of hepatocellular carcinoma with portal vein tumour thrombosis: a systematic review of comparative studies. <i>Przegląd Gastroenterologiczny</i> , 2015, 3, 142-147.	0.3	9
78	The Impact of Tumor Size on Long-Term Survival Outcomes After Resection of Solitary Hepatocellular Carcinoma: Single-Institution Experience with 2558 Patients. <i>Journal of Gastrointestinal Surgery</i> , 2015, 19, 1281-1290.	0.9	122
79	Combined AFP-CRUT with microvascular invasion accurately predicts mortality risk in patients with hepatocellular carcinoma following curative liver resection. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 1127-1138.	1.4	2
80	Expression of NEDD9 in hepatocellular carcinoma and its clinical significance. <i>Oncology Reports</i> , 2015, 33, 2375-2383.	1.2	14
81	Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Portal Vein Thrombosis: Impact of Early Response to 4 Weeks of Treatment. <i>Liver Cancer</i> , 2015, 4, 228-240.	4.2	41
82	Prognosis of untreated hepatocellular carcinoma. <i>Hepatology</i> , 2015, 61, 184-190.	3.6	188
83	Preoperative ultrasound features as prognostic factors for patients with hepatocellular carcinoma. <i>Radiologia Medica</i> , 2015, 120, 504-510.	4.7	2
84	High level of serum protein DKK1 predicts poor prognosis for patients with hepatocellular carcinoma after hepatectomy. <i>Hepatic Oncology</i> , 2015, 2, 231-244.	4.2	13
85	Impact of Steatosis on Prognosis of Patients with Early-Stage Hepatocellular Carcinoma After Hepatic Resection. <i>Annals of Surgical Oncology</i> , 2015, 22, 2253-2261.	0.7	31
86	Comparison of Transarterial Chemoembolization and Hepatic Resection for Large Solitary Hepatocellular Carcinoma: A Propensity Score Analysis. <i>Journal of Vascular and Interventional Radiology</i> , 2015, 26, 651-659.	0.2	32
87	Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma and Child-Pugh A or B cirrhosis. <i>Oncology Letters</i> , 2015, 9, 1628-1632.	0.8	25
88	Incidental tumor necrosis caused by the interventional alteration of hepatic arterial flow in patients with advanced hepatocellular carcinoma. <i>Clinical Journal of Gastroenterology</i> , 2015, 8, 41-46.	0.4	2
89	Tumor markers are more useful in patients undergoing surveillance for hepatocellular carcinoma with unreliable results by ultrasonography. <i>Hepatology Research</i> , 2015, 45, 415-422.	1.8	7
90	Clinicopathological Predictors of Poor Survival and Recurrence After Curative Resection in Hepatocellular Carcinoma Without Portal Vein Tumor Thrombosis. <i>Pathology and Oncology Research</i> , 2015, 21, 131-138.	0.9	21
91	Clinical characteristics, treatment, and prognosis of non-B, non-C hepatocellular carcinoma: a large retrospective multicenter cohort study. <i>Journal of Gastroenterology</i> , 2015, 50, 350-360.	2.3	144

#	ARTICLE	IF	CITATIONS
92	Neutrophil-to-lymphocyte ratio for the prognostic assessment of hepatocellular carcinoma: A systematic review and meta-analysis of observational studies. <i>Oncotarget</i> , 2016, 7, 45283-45301.	0.8	93
93	Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2016, 22, 262.	1.4	96
94	MBD2 as a novel marker associated with poor survival of patients with hepatocellular carcinoma after hepatic resection. <i>Molecular Medicine Reports</i> , 2016, 14, 1617-1623.	1.1	5
95	Refining prognosis after transcatheter arterial chemoembolization for hepatocellular carcinoma. <i>Liver International</i> , 2016, 36, 729-736.	1.9	62
96	Association of Histone Methyltransferase G9a and Overall Survival After Liver Resection of Patients With Hepatocellular Carcinoma With a Median Observation of 40 Months. <i>Medicine (United States)</i> , 2016, 95, e2493.	0.4	16
97	A prognostic index for patients within the intermediate stage of hepatocellular carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 592-598.	0.8	1
98	A Novel and Validated Inflammation-Based Score (IBS) Predicts Survival in Patients With Hepatocellular Carcinoma Following Curative Surgical Resection. <i>Medicine (United States)</i> , 2016, 95, e2784.	0.4	30
99	Molecular alterations in the carcinogenesis and progression of hepatocellular carcinoma: Tumor factors and background liver factors. <i>Oncology Letters</i> , 2016, 12, 3662-3668.	0.8	14
100	Aberrant methylation of TRIM58 in hepatocellular carcinoma and its potential clinical implication. <i>Oncology Reports</i> , 2016, 36, 811-818.	1.2	27
101	Phase I study of nintedanib in Japanese patients with advanced hepatocellular carcinoma and liver impairment. <i>Cancer Science</i> , 2016, 107, 1791-1799.	1.7	6
102	Long noncoding RNA glypican 3 (GPC3) antisense transcript 1 promotes hepatocellular carcinoma progression via epigenetically activating GPC3. <i>FEBS Journal</i> , 2016, 283, 3739-3754.	2.2	125
103	Association between age and overall survival of patients with hepatocellular carcinoma after hepatic resection. <i>Journal of Surgical Oncology</i> , 2016, 114, 966-970.	0.8	16
104	Preoperative γ -glutamyl transpeptidase to platelet ratio (GPR) is an independent prognostic factor for HBV-related hepatocellular carcinoma after curative hepatic resection. <i>Medicine (United States)</i> , 2016, 95, e4087.	0.4	22
105	Factors affecting the recurrence and survival of hepatocellular carcinoma after hepatectomy: a retrospective study of 601 Chinese patients. <i>Clinical and Translational Oncology</i> , 2016, 18, 831-840.	1.2	37
106	Multiplication of Tumor Volume by Two Tumor Markers Is a Post-Resection Prognostic Predictor for Solitary Hepatocellular Carcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2016, 20, 1807-1820.	0.9	36
107	Clinicopathological indices to predict hepatocellular carcinoma molecular classification. <i>Liver International</i> , 2016, 36, 108-118.	1.9	93
108	Regional differences in sorafenib-treated patients with hepatocellular carcinoma: GIDEON observational study. <i>Liver International</i> , 2016, 36, 1196-1205.	1.9	44
109	Impact of intermittent portal clamping on the early recurrence of hepatocellular carcinoma after surgery. <i>Surgery Today</i> , 2016, 46, 1290-1295.	0.7	15

#	ARTICLE	IF	CITATIONS
110	Hypermethylation of ACP1, BMP4, and TSPYL5 in Hepatocellular Carcinoma and Their Potential Clinical Significance. <i>Digestive Diseases and Sciences</i> , 2016, 61, 149-157.	1.1	31
111	The role of portal vein embolization in the surgical management of primary hepatobiliary cancers. A systematic review. <i>European Journal of Surgical Oncology</i> , 2017, 43, 32-41.	0.5	92
112	Real-World Data for the Evaluation of Transarterial Radioembolization versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. <i>Value in Health</i> , 2017, 20, 336-344.	0.1	29
113	Is the Hong Kong Liver Cancer Staging System Ready to Replace the Barcelona Clinic Liver Cancer System?. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 756-758.	2.4	1
114	Lymphocyte to monocyte ratio and neutrophil to lymphocyte ratio are superior inflammation-based predictors of recurrence in patients with hepatocellular carcinoma after hepatic resection. <i>Journal of Surgical Oncology</i> , 2017, 115, 718-728.	0.8	51
115	Expression of GRK2 and IGF1R in hepatocellular carcinoma: clinicopathological and prognostic significance. <i>Journal of Clinical Pathology</i> , 2017, 70, 754-759.	1.0	17
116	Prognostic value of site-specific extra-hepatic disease in hepatocellular carcinoma: a SEER database analysis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 695-701.	1.4	42
117	Nomogram prediction of individual prognosis of patients with hepatocellular carcinoma. <i>BMC Cancer</i> , 2017, 17, 91.	1.1	48
118	Impact of viral hepatitis aetiology on survival outcomes in hepatocellular carcinoma: A large multicentre cohort study. <i>Journal of Viral Hepatitis</i> , 2017, 24, 982-989.	1.0	17
119	Barcelona clinic liver cancer-stage C hepatocellular carcinoma. <i>Medicine (United States)</i> , 2017, 96, e6745.	0.4	21
120	Prognostic Nomograms Stratify Survival of Patients with Hepatocellular Carcinoma Without Portal Vein Tumor Thrombosis After Curative Resection. <i>Oncologist</i> , 2017, 22, 561-569.	1.9	35
121	Edmondson-Steiner grade: A crucial predictor of recurrence and survival in hepatocellular carcinoma without microvascular invasion. <i>Pathology Research and Practice</i> , 2017, 213, 824-830.	1.0	73
122	The diagnosis and treatment of hepatocellular carcinoma. <i>Seminars in Diagnostic Pathology</i> , 2017, 34, 153-159.	1.0	484
123	Nomograms for prediction of long-term survival in elderly patients after partial hepatectomy for hepatocellular carcinoma. <i>Surgery</i> , 2017, 162, 1231-1240.	1.0	9
124	Oroxylin A activates PKM1/HNF4 alpha to induce hepatoma differentiation and block cancer progression. <i>Cell Death and Disease</i> , 2017, 8, e2944-e2944.	2.7	57
125	Using receiver operating characteristic curves to evaluate the diagnostic value of the combination of multislice spiral CT and alpha-fetoprotein levels for small hepatocellular carcinoma in cirrhotic patients. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2017, 16, 303-309.	0.6	7
126	Communicative reprogramming non-curative hepatocellular carcinoma with low-dose metronomic chemotherapy, COX-2 inhibitor and PPAR-gamma agonist: a phase II trial. <i>Medical Oncology</i> , 2017, 34, 192.	1.2	26
127	Natural History of T1N0M0 Hepatocellular Carcinoma: Large-Scale Study in the United States. <i>Oncology</i> , 2017, 93, 233-242.	0.9	1

#	ARTICLE	IF	CITATIONS
128	Glasgow prognostic score predicts therapeutic outcome after hepatic resection for hepatocellular carcinoma. <i>Oncology Letters</i> , 2017, 14, 293-298.	0.8	16
129	ABO blood type correlates with survival in hepatocellular carcinoma following hepatectomy. <i>Scientific Reports</i> , 2017, 7, 4412.	1.6	15
130	Simplified HCC-ART score for highly sensitive detection of small-sized and early-stage hepatocellular carcinoma in the widely used Okuda, CLIP, and BCLC staging systems. <i>International Journal of Clinical Oncology</i> , 2017, 22, 332-339.	1.0	10
131	Subclassification of patients with intermediate-stage (Barcelona Clinic Liver Cancer stage-B) hepatocellular carcinoma using the up-to-seven criteria and serum tumor markers. <i>Hepatology International</i> , 2017, 11, 105-114.	1.9	40
132	Expression and Significances of G-Protein-Coupled Receptor Kinase 3 in Hepatocellular Carcinoma. <i>Journal of Cancer</i> , 2017, 8, 1972-1978.	1.2	8
133	Preoperative Carbohydrate Antigen 19-9: Its Neglected Role in Alpha-Fetoprotein-Negative Hepatocellular Carcinoma Patients. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 2025-2032.	0.9	13
134	Down-regulation of metabolic proteins in hepatocellular carcinoma with portal vein thrombosis. <i>Clinical Proteomics</i> , 2017, 14, 29.	1.1	9
135	Adverse impact of intermittent portal clamping on long-term postoperative outcomes in hepatocellular carcinoma. <i>Annals of the Royal College of Surgeons of England</i> , 2017, 99, 22-27.	0.3	10
136	Sarcopenia Predicts Reduced Survival in Patients with Hepatocellular Carcinoma at First Diagnosis. <i>Annals of Hepatology</i> , 2017, 16, 107-114.	0.6	59
137	Medical Management of Hepatocellular Carcinoma. <i>Journal of Oncology Practice</i> , 2017, 13, 356-364.	2.5	42
138	Intensity-modulated radiotherapy for hepatocellular carcinoma: dosimetric and clinical results. <i>Oncotarget</i> , 2017, 8, 59965-59976.	0.8	22
139	A new prognostic score can predict survival after hepatocellular carcinoma treatment in a cohort of 1302 Egyptian hepatocellular carcinoma patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 514-519.	0.8	3
140	Temporal trends in disease presentation and survival of patients with hepatocellular carcinoma: A real-world experience from 1998 to 2015. <i>Cancer</i> , 2018, 124, 2588-2598.	2.0	36
141	Advanced Hepatocellular Carcinoma: Pretreatment Contrast-enhanced CT Texture Parameters as Predictive Biomarkers of Survival in Patients Treated with Sorafenib. <i>Radiology</i> , 2018, 288, 445-455.	3.6	84
142	Conditional survival of patients with hepatocellular carcinoma: results from the Surveillance, Epidemiology, and End Results registry. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 515-523.	1.4	33
143	Treatment at a high-volume centre is associated with improved survival among patients with non-metastatic hepatocellular carcinoma. <i>Liver International</i> , 2018, 38, 665-675.	1.9	8
144	Quality of life as a prognostic factor for survival in hepatocellular carcinoma. <i>Liver International</i> , 2018, 38, 885-894.	1.9	25
145	Combination with CK19 Might Increase the Prognostic Power of Hep Par 1 in Hepatocellular Carcinoma after Curative Resection. <i>Journal of Investigative Surgery</i> , 2018, 31, 412-419.	0.6	8

#	ARTICLE	IF	CITATIONS
146	A new scoring model predicting macroscopic vascular invasion of early-intermediate hepatocellular carcinoma. <i>Medicine (United States)</i> , 2018, 97, e13536.	0.4	6
147	Clinical and prognostic significance of circulating levels of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma. <i>Oncotarget</i> , 2018, 9, 37721-37732.	0.8	16
148	Single institution experience of sorafenib for advanced HCC in a US tertiary care hospital. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 833-839.	0.6	4
149	Association and interaction between model for end-stage liver disease score and minimally invasive treatment with regard to mortality of patients with hepatitis B virus-associated hepatocellular carcinoma and portal vein tumor thrombi. <i>Oncology Letters</i> , 2019, 17, 119-126.	0.8	0
150	Signature of survival: a 18F-FDG PET based whole-liver radiomic analysis predicts survival after 90Y-TARE for hepatocellular carcinoma. <i>Oncotarget</i> , 2018, 9, 4549-4558.	0.8	42
151	90Y TOF-PET based EUD reunifies patient survival prediction in resin and glass microspheres radioembolization of HCC tumours. <i>Physics in Medicine and Biology</i> , 2018, 63, 245010.	1.6	23
152	Carbohydrate Antigen 19-9 Increases the Predictive Efficiency of α -Fetoprotein for Prognosis of Resected Hepatocellular Carcinoma. <i>American Surgeon</i> , 2018, 84, 80-85.	0.4	4
153	Evaluation of survival of patients with hepatocellular carcinoma: A comparative analysis of prognostic systems. <i>PLoS ONE</i> , 2018, 13, e0194922.	1.1	13
154	Fibrinogen and C-reactive protein score is a prognostic index for patients with hepatocellular carcinoma undergoing curative resection: a prognostic nomogram study. <i>Journal of Cancer</i> , 2018, 9, 148-156.	1.2	21
155	Hepatic resection for elderly patients with hepatocellular carcinoma: a systematic review of more than 17,000 patients. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 1059-1068.	1.4	19
156	The prognostic analysis of different metastatic patterns in advanced liver cancer patients: A population based analysis. <i>PLoS ONE</i> , 2018, 13, e0200909.	1.1	8
157	Preoperative prealbumin level as an independent predictor of long-term prognosis after liver resection for hepatocellular carcinoma: a multi-institutional study. <i>Hpb</i> , 2019, 21, 157-166.	0.1	31
158	The Robust Classification Model Based on Combinatorial Features. <i>IEEE/ACM Transactions on Computational Biology and Bioinformatics</i> , 2019, 16, 650-657.	1.9	6
159	High thymidylate synthase gene expression predicts poor outcome after resection of hepatocellular carcinoma. <i>PLoS ONE</i> , 2019, 14, e0219469.	1.1	8
160	Factors Influencing the Efficacy of Anti-PD-1 Therapy in Chinese Patients with Advanced Melanoma. <i>Journal of Oncology</i> , 2019, 2019, 1-8.	0.6	9
161	Jak-Stat Signaling Induced by Interleukin-6 Family Cytokines in Hepatocellular Carcinoma. <i>Cancers</i> , 2019, 11, 1704.	1.7	81
162	Liquid Biopsy for Hepatocellular Carcinoma. <i>Current Hepatology Reports</i> , 2019, 18, 390-399.	0.4	1
163	Normal Alpha-Fetoprotein Hepatocellular Carcinoma: Are They Really Normal?. <i>Journal of Clinical Medicine</i> , 2019, 8, 1736.	1.0	28

#	ARTICLE	IF	CITATIONS
164	Circulating miRâ€“130bâ€“ and miRâ€“21â€“ based diagnostic markers and therapeutic targets for hepatocellular carcinoma. <i>Molecular Genetics & Genomic Medicine</i> , 2019, 7, e1012.	0.6	34
165	Apatinib for Patients With Sorafenib-Refractory Advanced Hepatitis B Virus Related Hepatocellular Carcinoma: Results of a Pilot Study. <i>Cancer Control</i> , 2019, 26, 107327481987221.	0.7	17
166	Transarterial chemoembolization with pirarubicin-eluting microspheres in patients with unresectable hepatocellular carcinoma: Preliminary results. <i>Journal of Interventional Medicine</i> , 2019, 2, 69-77.	0.2	3
167	Stereotactic body radiation therapy for hepatocellular carcinoma: Practice patterns, dose selection and factors impacting survival. <i>Cancer Medicine</i> , 2019, 8, 928-938.	1.3	16
168	Preoperative serum ferritin is an independent prognostic factor for liver cancer after hepatectomy. <i>Surgical Oncology</i> , 2019, 29, 159-167.	0.8	11
169	Machine-learning Approach for the Development of a Novel Predictive Model for the Diagnosis of Hepatocellular Carcinoma. <i>Scientific Reports</i> , 2019, 9, 7704.	1.6	82
170	Platelet-albumin-bilirubin grade: Risk stratification of liver failure, prognosis after resection for hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2019, 51, 1430-1437.	0.4	23
171	Hepatocellular carcinoma macroscopic gross appearance on imaging: predictor of outcome after transarterial chemoembolization in a real-life multicenter French cohort. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1414-1423.	0.8	4
172	Childâ€“Pugh Classification: Time to Abandon?. <i>Seminars in Liver Disease</i> , 2019, 39, 096-103.	1.8	49
173	Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade. <i>Cancers</i> , 2020, 12, 1862.	1.7	47
174	Stereotactic Body Radiotherapy as a Salvage Therapy after Incomplete Radiofrequency Ablation for Hepatocellular Carcinoma: A Retrospective Cohort Study. <i>Journal of Oncology</i> , 2020, 2020, 1-9.	0.6	6
175	<p>Evaluation of Multiple Prognostic Factors of Hepatocellular Carcinoma with Intra-Voxel Incoherent Motions Imaging by Extracting the Histogram Metrics</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 6019-6031.	0.9	19
176	Apatinib treatment may improve survival outcomes of patients with hepatitis B virus-related sorafenib-resistant hepatocellular carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592093742.	1.4	9
177	Realâ€“world efficacy and safety of immune checkpoint inhibitors in advanced hepatocellular carcinoma: Experience of a tertiary Asian Center. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, e249-e261.	0.7	18
178	<p>Prognosis Factors of Young Patients Undergoing Curative Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma: A Multicenter Study</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 6597-6606.	0.9	5
179	The Prediction of Survival in Hepatocellular Carcinoma Based on A Four Long Non-coding RNAs Expression Signature. <i>Journal of Cancer</i> , 2020, 11, 4132-4144.	1.2	7
180	Total tumor volume as a prognostic value for survival following liver resection in patients with hepatocellular carcinoma. Retrospective cohort study. <i>Annals of Medicine and Surgery</i> , 2020, 54, 47-53.	0.5	12
181	Serum metabolites may be useful markers to assess vascular invasion and identify normal alpha-fetoprotein in hepatocellular carcinoma undergoing liver resection: a pilot study. <i>World Journal of Surgical Oncology</i> , 2020, 18, 121.	0.8	10

#	ARTICLE	IF	CITATIONS
182	Nomogram for Individualized Prediction of Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis on Conservative Treatment. <i>BioMed Research International</i> , 2020, 2020, 1-9.	0.9	1
183	Predicting the Outcome of Transcatheter Arterial Embolization Therapy for Unresectable Hepatocellular Carcinoma Based on Radiomics of Preoperative Multiparameter MRI. <i>Journal of Magnetic Resonance Imaging</i> , 2020, 52, 1083-1090.	1.9	35
184	Hepatocellular carcinoma surveillance, early detection and survival in a privately insured US cohort. <i>Liver International</i> , 2020, 40, 947-955.	1.9	15
185	Utility of Liquid Biopsy Analysis in Detection of Hepatocellular Carcinoma, Determination of Prognosis, and Disease Monitoring: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2879-2902.e9.	2.4	81
186	Increased Survival Benefit of Adjuvant Intra-arterial Infusion Chemotherapy in HCC Patients with Portal Vein Infiltration after Hepatectomy. <i>World Journal of Surgery</i> , 2020, 44, 2770-2776.	0.8	9
187	Morphophenotypic Classification of Hepatocellular Carcinoma: the Biliary/Stem Cell Subgroup and Worst Outcome—Implications on Patient Selection. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 698-707.	0.9	1
188	The PPRD score stratifies patients with hepatocellular carcinoma and portal vein tumor thrombus treated with sorafenib plus transarterial chemoembolization. <i>European Radiology</i> , 2021, 31, 232-243.	2.3	7
189	Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2. <i>JHEP Reports</i> , 2021, 3, 100215.	2.6	31
190	Hepatitis C—positive Black patients develop hepatocellular carcinoma at earlier stages of liver disease and present with a more aggressive phenotype. <i>Cancer</i> , 2021, 127, 1395-1406.	2.0	16
191	Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab. <i>British Journal of Cancer</i> , 2021, 124, 1388-1397.	2.9	39
193	Preoperative Alpha-Fetoprotein Has No Prognostic Role in Small Hepatocellular Carcinoma in Non-Cirrhotic Patients After Surgical Resection. <i>Turkish Journal of Gastroenterology</i> , 2021, 32, 133-140.	0.4	0
194	Radiofrequency ablation vs surgical resection in elderly patients with hepatocellular carcinoma in Milan criteria. <i>World Journal of Gastroenterology</i> , 2021, 27, 2205-2218.	1.4	14
195	A Simple Prognostic Scoring System for Hepatocellular Carcinoma Treated with Selective Internal Radiation Therapy. <i>Digestive Diseases</i> , 2022, 40, 322-334.	0.8	3
196	Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiology. <i>Liver International</i> , 2021, 41, 2759-2767.	1.9	5
197	Hepatic vein tumor thrombosis in patients with hepatocellular carcinoma: Prevalence and clinical significance. <i>United European Gastroenterology Journal</i> , 2021, 9, 590-597.	1.6	9
198	Implication of human endogenous retrovirus W family envelope in hepatocellular carcinoma promotes MEK/ERK-mediated metastatic invasiveness and doxorubicin resistance. <i>Cell Death Discovery</i> , 2021, 7, 177.	2.0	28
199	Prognostic value of the ALBI grade among patients with single hepatocellular carcinoma without macrovascular invasion. <i>Medicine (United States)</i> , 2021, 100, e26265.	0.4	10
200	The prognostic and diagnostic significance of the neutrophil-to-lymphocyte ratio in hepatocellular carcinoma: a prospective controlled study. <i>British Journal of Cancer</i> , 2021, 125, 714-716.	2.9	26

#	ARTICLE	IF	CITATIONS
201	What is the optimal surgical treatment for hepatocellular carcinoma beyond the debate between anatomical versus non-anatomical resection?. <i>Surgery Today</i> , 2022, 52, 871-880.	0.7	2
202	Prognostic factors of unresectable hepatocellular carcinoma treated with yttrium-90 radioembolization: results from a large cohort over 13 years at a single center. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 1718-1731.	0.6	2
203	Development of pre and postoperative nomograms to predict individual survival for ideal liver resection candidates with hepatocellular carcinoma. <i>Liver International</i> , 2021, 41, 2974-2985.	1.9	6
204	Radiomics Signature: A potential biomarker for the prediction of survival in Advanced Hepatocellular Carcinoma. <i>International Journal of Medical Sciences</i> , 2021, 18, 2276-2284.	1.1	13
205	Staging of Hepatocellular Carcinoma. , 2012, , 161-175.		1
206	A New Model to Estimate Prognosis in Patients with Hepatocellular Carcinoma after Yttrium-90 Radioembolization. <i>PLoS ONE</i> , 2013, 8, e82225.	1.1	19
207	Prognostic Implications of Arginase and Cytokeratin 19 Expression in Hepatocellular Carcinoma After Curative Hepatectomy: Correlation With Recurrence-Free Survival. <i>Gastroenterology Research</i> , 2019, 12, 78-87.	0.4	10
208	Hepatic resection for hepatocellular carcinoma in the octogenarian: is it justified?. <i>Aging</i> , 2019, 11, 1537-1550.	1.4	9
209	Overexpression of EMT-inducing transcription factors as a potential poor prognostic factor for hepatocellular carcinoma in Asian populations: A meta-analysis. <i>Oncotarget</i> , 2017, 8, 59500-59508.	0.8	19
210	High KIF18A expression correlates with unfavorable prognosis in primary hepatocellular carcinoma. <i>Oncotarget</i> , 2014, 5, 10271-10279.	0.8	47
211	Elevated preoperative aspartate aminotransferase to lymphocyte ratio index as an independent prognostic factor for patients with hepatocellular carcinoma after hepatic resection. <i>Oncotarget</i> , 2015, 6, 19217-19227.	0.8	33
212	A novel prognostic biomarker SPC24 up-regulated in hepatocellular carcinoma. <i>Oncotarget</i> , 2015, 6, 41383-41397.	0.8	33
213	Prognosis of hepatocellular carcinoma with portal vein tumor thrombus:assessment based on clinical and computer tomography characteristics. <i>Acta Medica Okayama</i> , 2012, 66, 131-41.	0.1	12
214	Sorafenib Combined with Radio-frequency Ablation Compared with Sorafenib Alone in Treatment of Hepatocellular Carcinoma Invading Portal Vein: A Western Randomized Controlled Trial. <i>Anticancer Research</i> , 2016, 36, 6179-6184.	0.5	35
215	High resolution multi-arterial phase MRI improves lesion contrast in chronic liver disease. <i>Clinical and Investigative Medicine</i> , 2015, 38, 90.	0.3	13
216	Predictive value of ^{18}F -fluorodeoxyglucose PET/CT for transarterial chemolipiodolization of hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2012, 18, 3215-22.	1.4	37
217	Alpha-fetoprotein: A controversial prognostic biomarker for small hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2013, 19, 328.	1.4	19
218	Hepatic artery infusion chemotherapy for advanced hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2015, 21, 3843.	1.4	56

#	ARTICLE	IF	CITATIONS
219	Prognostic roles of preoperative α -fetoprotein and des- γ -carboxy prothrombin in hepatocellular carcinoma patients. <i>World Journal of Gastroenterology</i> , 2015, 21, 4933.	1.4	47
220	Analysis of aggressiveness factors in hepatocellular carcinoma patients undergoing transarterial chemoembolization. <i>World Journal of Gastroenterology</i> , 2018, 24, 1641-1649.	1.4	8
221	Serum Dickkopf-1 as a biomarker for the diagnosis of hepatocellular carcinoma. <i>Chinese Clinical Oncology</i> , 2012, 1, 4.	0.4	3
222	Predictors of 5 year survival rate in hepatocellular carcinoma patients. <i>Journal of Research in Medical Sciences</i> , 2019, 24, 86.	0.4	65
223	Sub-classification of Advanced-Stage Hepatocellular Carcinoma: A Cohort Study Including 612 Patients Treated with Sorafenib. <i>Cancer Research and Treatment</i> , 2018, 50, 366-373.	1.3	15
224	Validation of prognostic impact of ADV score for resection of hepatocellular carcinoma: analysis using Korea Liver Cancer Registry Database. <i>Annals of Surgical Treatment and Research</i> , 2020, 98, 235.	0.4	7
225	Current state and clinical outcome in Turkish patients with hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2018, 10, 51-61.	0.8	7
226	^{18}F -FDG PET CT as a prognostic factor in hepatocellular carcinoma. <i>Turkish Journal of Gastroenterology</i> , 2015, 26, 344-351.	0.4	13
227	DEP Domain Containing 1 is a Novel Diagnostic Marker and Prognostic Predictor for Hepatocellular Carcinoma. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015, 15, 10917-10922.	0.5	26
228	Survival and Prognostic Factors for Hepatocellular Carcinoma: an Egyptian Multidisciplinary Clinic Experience. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014, 15, 3915-3920.	0.5	35
229	Clinicopathologic and Prognostic Significance of Carboxyl Terminus of Hsp70-interacting Protein in HBV-related Hepatocellular Carcinoma. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015, 16, 3709-3713.	0.5	3
230	Molecular classification of hepatocellular carcinoma: prognostic importance and clinical applications. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 15-29.	1.2	13
231	HEPATOCELLULAR CARCINOMA; <i>The Professional Medical Journal</i> , 2018, 21, 1222-1226.	0.0	0
232	A Novel Prognostic Score based on Serum Alpha-Fetoprotein, Number of Nodules, and MYC Gene Status Predicts Prognosis of Patients after Liver Resection for Hepatocellular Carcinoma. <i>Journal of Integrative Oncology</i> , 2015, 05, .	0.3	0
233	The potential involvement of the cofactor of BRCA1 in hepatocellular carcinoma pathogenesis. <i>Advances in Modern Oncology Research</i> , 2016, 2, 224.	0.1	2
234	Biomarkers for Hepatocellular Carcinoma in East Asia. <i>Biomarkers in Disease</i> , 2017, , 901-925.	0.0	0
235	Lebertumoren. , 2018, , 397-441.		0
236	Prognostic Role of Serum Alpha-Fetoprotein in Hepatocellular Carcinoma Patients with Radiofrequency Ablation. <i>Afro-Egyptian Journal of Infectious and Endemic Diseases</i> , 2018, 8, 164-173.	0.1	0

#	ARTICLE	IF	CITATIONS
237	Liver Cirrhosis of the Viral Etiology in Children. Detskie Infekcii (Moskva), 2018, 17, 29-33.	0.1	0
238	Precision Locoregional Therapies for Hepatocellular Carcinoma: Percutaneous Ablation and Radiotherapy. Molecular and Translational Medicine, 2019, , 195-224.	0.4	3
240	Development of a novel prognostic nomogram for the early recurrence of liver cancer after curative hepatectomy. Annals of Translational Medicine, 2021, 9, 1541-1541.	0.7	6
241	Survival improvement and prognosis for hepatocellular carcinoma: analysis of the SEER database. BMC Cancer, 2021, 21, 1157.	1.1	43
242	Prognostic evaluation and immune infiltration analysis of five bioinformatic selected genes in hepatocellular carcinoma. Journal of Cellular and Molecular Medicine, 2021, 25, 11128-11141.	1.6	3
243	The Relationship Between Blood Neutrophil to Lymphocyte Ratio and Tumor Size, Tumor Number, Macrovascular Invasion in Patients with Hepatocellular Carcinoma. Acta Medica Alanya, 2019, 3, 207-212.	0.2	1
244	Clinical outcomes of surgical resection versus radiofrequency ablation in very-early-stage hepatocellular carcinoma: a propensity score matching analysis. BMC Gastroenterology, 2021, 21, 418.	0.8	13
245	Mast cells, disease and gastrointestinal cancer: A comprehensive review of recent findings. Translational Gastrointestinal Cancer, 2012, 1, 138-150.	3.0	22
246	Overexpression of sineoculis homeobox homolog 1 predicts poor prognosis of hepatocellular carcinoma. International Journal of Clinical and Experimental Pathology, 2014, 7, 3018-27.	0.5	11
247	Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: From Epidemiology to Diagnostic Approach. Cancers, 2021, 13, 5844.	1.7	27
248	Correlation of Clinicopathological Profile, Prognostic Factors, and Survival Outcomes with Baseline Alfa-Fetoprotein Levels in Patients With Hepatocellular Carcinoma: A Biomarker that is Bruised but Not Broken. Journal of Clinical and Experimental Hepatology, 2022, 12, 841-852.	0.4	4
249	Do changes in inflammatory markers predict hepatocellular carcinoma recurrence and survival after liver transplantation?. Annals of Hepato-biliary-pancreatic Surgery, 2022, 26, 40-46.	0.1	3
250	Prefoldin proteins 2/6, and HMG20B are regulated by HDAC1, HDAC3 and are novel therapeutic and prognostic biomarkers in hepatocellular carcinoma. Journal of King Saud University - Science, 2022, 34, 101812.	1.6	0
251	A nomogram for predicting the risk of postoperative recurrence of hepatitis B virus-related hepatocellular carcinoma in patients with high preoperative serum glutamyl transpeptidase. Journal of Gastrointestinal Oncology, 2022, 13, 298-310.	0.6	4
252	A Dual-Filtration System for Single-Cell Sequencing of Circulating Tumor Cells and Clusters in HCC. Hepatology Communications, 2022, 6, 1482-1491.	2.0	6
253	Sarcopenia in hepatocellular carcinoma: Current knowledge and future directions. World Journal of Gastroenterology, 2022, 28, 432-448.	1.4	36
254	A hepatocellularis carcinoma komplex kezelése.. Orvosi Hetilap, 2022, 162, 2-31.	0.1	1
255	Tenofovir vs. entecavir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative resection. Journal of Gastroenterology, 2022, 57, 185-198.	2.3	16

#	ARTICLE	IF	CITATIONS
256	Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1). <i>Journal of Clinical Oncology</i> , 2022, 40, 468-480.	0.8	98
257	Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210802.	1.4	43
258	Distance Matters: Correlation of Hepatocellular Carcinoma Nodule Distance to Overall Survival. <i>Digestive Diseases</i> , 2023, 41, 107-114.	0.8	0
259	Development and validation of a therapy-independent hepatocellular carcinoma survival prediction score. <i>Liver Cancer International</i> , 0, , .	0.2	2
260	Epithelial-Mesenchymal Transition Markers in HCV-Associated Hepatocellular Carcinoma: A Multivariate Follow Up Study. <i>Asian Pacific Journal of Cancer Prevention</i> , 2022, 23, 839-849.	0.5	5
261	The Prognostic Values of Neutrophil-to-lymphocyte Ratio and Platelet-to-Lymphocyte Ratio at Baseline in Predicting the In-hospital Mortality in Black African Patients with Advanced Hepatocellular Carcinoma in Palliative Treatment: A Comparative Cohort Study. <i>Hepatic Medicine: Evidence and Research</i> , 2021, Volume 13, 123-134.	0.9	6
262	Development and External Validation of the Munich Sorafenib Evaluation Score for Hepatocellular Carcinoma. <i>Digestive Diseases</i> , 2023, 41, 268-281.	0.8	0
263	Efficacy and Safety of Apatinib in Advanced Hepatocellular Carcinoma: A Multicenter Real World Retrospective Study. <i>Frontiers in Pharmacology</i> , 2022, 13, .	1.6	4
264	Clinical Course and Outcomes of Patients with Nonalcoholic Fatty Liver Disease-Related Hepatocellular Cancer (NAFLD-HCC). <i>Digestive Diseases and Sciences</i> , 0, , .	1.1	2
265	Trends in radiotherapy administration in the management of hepatocellular carcinoma: Analysis of a Korean tertiary hospital registry of hepatocellular carcinoma patients diagnosed between 2005 and 2017. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
266	Efficacy of Adjuvant Transarterial Chemoembolization Combined Antiviral Therapy for HBV-Related HCC with MVI after Hepatic Resection: A Multicenter Study. <i>Asian Pacific Journal of Cancer Prevention</i> , 2022, 23, 2695-2703.	0.5	1
268	Má»T Sá»·Äá»C Äá»M LÃ,M SÃENG, Cá»-N LÃ,M SÃENG VÃ HÃENH á»CNH Há»CEC TRÃŠN Bá»†NH NHÃ,N UNG THÆ- Blá»U MÃ» Tá» THIá»†P NÃŠT Má»CH HÃ»A CHá»T SIÃŠU CHá»CEN Lá»CEC Tá»I Bá»†NH Vlá»†N K. <i>Y Hoc Viet Nam</i> , 2022, 519, .	0.0	0
270	Prognostic Factors for Overall Survival in Patients with HCV-Related HCC Undergoing Molecular Targeted Therapies: Beyond a Sustained Virological Response. <i>Cancers</i> , 2022, 14, 4850.	1.7	0
271	Atezolizumab plus bevacizumab in patients with child-Pugh B advanced hepatocellular carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592211485.	1.4	6
272	Cd34 Immunostaining Adds Specificity To Microvascular invasion Analysis in Hepatocellular Carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 10, 91-98.	1.8	0
273	Inflammation-Related Marker NrLR Predicts Prognosis in AFP-Negative HCC Patients After Curative Resection. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 10, 193-202.	1.8	1
274	Development of Prognostic Features of Hepatocellular Carcinoma Based on Metabolic Gene Classification and Immune and Oxidative Stress Characteristic Analysis. <i>Oxidative Medicine and Cellular Longevity</i> , 2023, 2023, 1-29.	1.9	1
275	CT texture analysis in predicting treatment response and survival in patients with hepatocellular carcinoma treated with transarterial chemoembolization using random forest models. <i>BMC Cancer</i> , 2023, 23, .	1.1	1

#	ARTICLE	IF	CITATIONS
276	Should we change the treatment plan in early hepatocellular carcinoma with chronic kidney disease?. BMC Surgery, 2023, 23, .	0.6	0
277	Comparison of local ablative therapies, including radiofrequency ablation, microwave ablation, stereotactic ablative radiotherapy, and particle radiotherapy, for inoperable hepatocellular carcinoma: a systematic review and meta-analysis. Experimental Hematology and Oncology, 2023, 12, .	2.0	3
281	Biomarkers for Hepatocellular Carcinoma in East Asia. Biomarkers in Disease, 2015, , 1-25.	0.0	0